Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes

Monica Gamez,Hesham E. Elhegni,Sarah Fawaz,Kwan Ho Ho,Neill W. Campbell,David A. Copland,Karen L. Onions,Matthew J. Butler,Elizabeth J. Wasson,Michael Crompton,Raina D. Ramnath,Yan Qiu,Yu Yamaguchi,Kenton P. Arkill,David O. Bates,Jeremy E. Turnbull,Olga V. Zubkova,Gavin I. Welsh,Denize Atan,Simon C. Satchell,Rebecca R. Foster
DOI: https://doi.org/10.1186/s12933-024-02133-1
IF: 8.949
2024-02-02
Cardiovascular Diabetology
Abstract:Diabetes mellitus is a chronic disease which is detrimental to cardiovascular health, often leading to secondary microvascular complications, with huge global health implications. Therapeutic interventions that can be applied to multiple vascular beds are urgently needed. Diabetic retinopathy (DR) and diabetic kidney disease (DKD) are characterised by early microvascular permeability changes which, if left untreated, lead to visual impairment and renal failure, respectively. The heparan sulphate cleaving enzyme, heparanase, has previously been shown to contribute to diabetic microvascular complications, but the common underlying mechanism which results in microvascular dysfunction in conditions such as DR and DKD has not been determined.
cardiac & cardiovascular systems,endocrinology & metabolism
What problem does this paper attempt to address?